McDermott David H, Gao Ji-Liang, Liu Qian, Siwicki Marie, Martens Craig, Jacobs Paejonette, Velez Daniel, Yim Erin, Bryke Christine R, Hsu Nancy, Dai Zunyan, Marquesen Martha M, Stregevsky Elina, Kwatemaa Nana, Theobald Narda, Long Priel Debra A, Pittaluga Stefania, Raffeld Mark A, Calvo Katherine R, Maric Irina, Desmond Ronan, Holmes Kevin L, Kuhns Douglas B, Balabanian Karl, Bachelerie Françoise, Porcella Stephen F, Malech Harry L, Murphy Philip M
Laboratory of Molecular Immunology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Research Technologies Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT 59840, USA.
Cell. 2015 Feb 12;160(4):686-699. doi: 10.1016/j.cell.2015.01.014. Epub 2015 Feb 5.
Chromothripsis is a catastrophic cellular event recently described in cancer in which chromosomes undergo massive deletion and rearrangement. Here, we report a case in which chromothripsis spontaneously cured a patient with WHIM syndrome, an autosomal dominant combined immunodeficiency disease caused by gain-of-function mutation of the chemokine receptor CXCR4. In this patient, deletion of the disease allele, CXCR4(R334X), as well as 163 other genes from one copy of chromosome 2 occurred in a hematopoietic stem cell (HSC) that repopulated the myeloid but not the lymphoid lineage. In competitive mouse bone marrow (BM) transplantation experiments, Cxcr4 haploinsufficiency was sufficient to confer a strong long-term engraftment advantage of donor BM over BM from either wild-type or WHIM syndrome model mice, suggesting a potential mechanism for the patient's cure. Our findings suggest that partial inactivation of CXCR4 may have general utility as a strategy to promote HSC engraftment in transplantation.
染色体碎裂是一种最近在癌症中被描述的灾难性细胞事件,其中染色体会经历大规模的缺失和重排。在此,我们报告了一例染色体碎裂自发治愈WHIM综合征患者的病例,WHIM综合征是一种由趋化因子受体CXCR4功能获得性突变引起的常染色体显性联合免疫缺陷疾病。在该患者中,疾病等位基因CXCR4(R334X)以及来自2号染色体一个拷贝上的其他163个基因在一个造血干细胞(HSC)中发生缺失,该造血干细胞重新填充了髓系而非淋巴系。在竞争性小鼠骨髓(BM)移植实验中,Cxcr4单倍体不足足以赋予供体骨髓相对于野生型或WHIM综合征模型小鼠骨髓强大的长期植入优势,这提示了该患者治愈的潜在机制。我们的研究结果表明,CXCR4的部分失活作为一种促进移植中造血干细胞植入的策略可能具有普遍适用性。